rs201728041
Variant summary
Our verdict is Likely pathogenic. The variant received 8 ACMG points: 8P and 0B. PVS1
The NM_000432.4(MYL2):c.184A>T(p.Lys62*) variant causes a stop gained change. The variant allele was found at a frequency of 0.00000929 in 1,613,846 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000432.4 stop_gained
Scores
Clinical Significance
Conservation
Publications
- hypertrophic cardiomyopathyInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- hypertrophic cardiomyopathy 10Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: ClinGen, G2P, PanelApp Australia, Labcorp Genetics (formerly Invitae)
- myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathyInheritance: AR Classification: MODERATE Submitted by: Ambry Genetics
- congenital fiber-type disproportion myopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- dilated cardiomyopathyInheritance: AD Classification: LIMITED Submitted by: ClinGen
- arrhythmogenic right ventricular cardiomyopathyInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 8 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| MYL2 | NM_000432.4 | c.184A>T | p.Lys62* | stop_gained | Exon 4 of 7 | ENST00000228841.15 | NP_000423.2 | |
| MYL2 | NM_001406745.1 | c.142A>T | p.Lys48* | stop_gained | Exon 3 of 6 | NP_001393674.1 | ||
| MYL2 | NM_001406916.1 | c.127A>T | p.Lys43* | stop_gained | Exon 4 of 7 | NP_001393845.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152112Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000795 AC: 2AN: 251478 AF XY: 0.00000736 show subpopulations
GnomAD4 exome AF: 0.00000821 AC: 12AN: 1461734Hom.: 0 Cov.: 32 AF XY: 0.00000825 AC XY: 6AN XY: 727192 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152112Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74274 show subpopulations
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:1
- -
Reported in association with HCM, though additional patient-specific details were not described (Alfares et al., 2015; Walsh et al., 2017); Not observed at significant frequency in large population cohorts (gnomAD); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene or region of a gene for which loss of function is not a well-established mechanism of disease; This variant is associated with the following publications: (PMID: 25611685, 27532257, 32453731) -
Hypertrophic cardiomyopathy Uncertain:2
This variant changes 1 nucleotide in exon 4 of the MYL2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. A functional study has shown that the mutant protein exhibits impaired localization to cytoskeleton, compared to wild-type (PMID: 32453731). This variant has been reported in one individual affected with hypertrophic cardiomyopathy (PMID: 27532257). This variant has been identified in 2/251478 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Clinical relevance of loss-of-function MYL2 truncation variants in autosomal dominant cardiovascular disorders is not clearly established. The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.Lys62X variant in MYL2 has been identified by our laboratory in 1 Caucasian adult with HCM. It was absent from large population studies. This nonsense variant leads to a premature termination codon at position 62, which is predicted to lead to a truncated or absent protein. Although this variant is predicted to be deleterious to the protein, heterozygous loss of function of this gene is not an established disease mechanism and it is unclear if these variant types play a role in disease. In summary, while there is some suspicion for a pathogenic role, the clinical significance of the p.Lys62X variant is uncertain. -
Hypertrophic cardiomyopathy 10 Uncertain:1
This sequence change creates a premature translational stop signal (p.Lys62*) in the MYL2 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in MYL2 cause disease. This variant is present in population databases (rs201728041, gnomAD 0.002%). This premature translational stop signal has been observed in individual(s) with hypertrophic cardiomyopathy (PMID: 27532257). ClinVar contains an entry for this variant (Variation ID: 164478). Algorithms developed to predict the effect of variants on gene product structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects MYL2 function (PMID: 32453731). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiomyopathy Uncertain:1
This variant changes 1 nucleotide in exon 4 of the MYL2 gene, creating a premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. A functional study has shown that the mutant protein exhibits impaired localization to cytoskeleton, compared to wild-type (PMID: 32453731). This variant has been reported in one individual affected with hypertrophic cardiomyopathy (PMID: 27532257). This variant has been identified in 2/251478 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Clinical relevance of loss-of-function MYL2 truncation variants in autosomal dominant cardiovascular disorders is not clearly established. The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at